NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $26.39
  • Forecasted Upside: 1,416.60 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.74
▲ +0.01 (0.58%)
1 month | 3 months | 12 months
Get New Corbus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRBP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$26.39
▲ +1,416.60% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Corbus Pharmaceuticals in the last 3 months. The average price target is $26.39, with a high forecast of $112.00 and a low forecast of $2.50. The average price target represents a 1,416.60% upside from the last price of $1.74.
Hold
The current consensus among 9 polled investment analysts is to hold stock in Corbus Pharmaceuticals. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/8/2020HC WainwrightLower Price TargetBuy$6.00 ➝ $3.00Medium
i
9/9/2020HC WainwrightLower Price TargetBuy$24.00 ➝ $6.00High
i
9/8/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
9/8/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$18.00 ➝ $2.50N/A
i
9/8/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$22.00 ➝ $3.00N/A
i
9/8/2020BTIG ResearchDowngradeBuy ➝ NeutralN/A
i
Rating by Dae Gon Ha at BTIG Research
9/8/2020Roth CapitalDowngradeBuy ➝ Neutral$40.00 ➝ $3.00N/A
i
Rating by E. Pierce at Roth Capital
8/7/2020HC WainwrightReiterated RatingBuy$24.00Medium
i
7/27/2020Jefferies Financial GroupBoost Price TargetBuy$17.00 ➝ $18.00High
i
7/7/2020Roth CapitalInitiated CoverageBuy$40.00High
i
Rating by E. Pierce at Roth Capital
6/29/2020OppenheimerReiterated RatingBuy$28.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
6/19/2020OppenheimerReiterated RatingBuy$28.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
6/16/2020BTIG ResearchInitiated CoverageBuy$22.00High
i
6/4/2020NomuraBoost Price TargetBuy$12.00 ➝ $32.00Low
i
6/4/2020Nomura InstinetBoost Price TargetBuy$12.00 ➝ $32.00Medium
i
5/13/2020NomuraReiterated RatingBuy$12.00Low
i
5/11/2020OppenheimerReiterated RatingBuy$28.00High
i
3/26/2020Nomura SecuritiesInitiated CoverageBuy$112.00High
i
12/23/2019HC WainwrightReiterated RatingBuy$24.00N/A
i
Rating by Andrew Fein at HC Wainwright
8/11/2019Royal Bank of CanadaReiterated RatingBuy$23.00Medium
i
6/24/2019HC WainwrightSet Price TargetBuy$24.00Low
i
Rating by Andrew Fein at HC Wainwright
5/10/2019HC WainwrightReiterated RatingBuy$24.00High
i
Rating by A. Fein at HC Wainwright
4/5/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$18.00 ➝ $18.00High
i
3/20/2019CIBCInitiated CoverageOutperform ➝ Outperform$28.00High
i
3/19/2019OppenheimerInitiated CoverageOutperform$28.00 ➝ $28.00Medium
i
3/12/2019Cantor FitzgeraldReiterated RatingBuy$38.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
1/11/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$36.00 ➝ $38.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
1/4/2019HC WainwrightReiterated RatingBuy$24.00Medium
i
Rating by A. Fein at HC Wainwright
12/26/2018HC WainwrightInitiated CoverageBuy ➝ Buy$24.00Medium
i
Rating by A. Fein at HC Wainwright
12/7/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$23.00High
i
10/24/2018B. RileyInitiated CoverageBuy ➝ Buy$22.00High
i
Rating by G. Zavoico at B. Riley
10/22/2018Cantor FitzgeraldReiterated RatingBuy$36.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
10/1/2018Cantor FitzgeraldSet Price TargetBuy$36.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
9/20/2018Cantor FitzgeraldSet Price TargetBuy$36.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
9/13/2018Cantor FitzgeraldSet Price TargetBuy$32.00 ➝ $36.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
8/8/2018Cantor FitzgeraldReiterated RatingBuy$32.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/25/2018Cantor FitzgeraldSet Price TargetBuy$32.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
5/10/2018Cantor FitzgeraldSet Price TargetBuy$32.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
3/13/2018Noble FinancialReiterated RatingBuyMedium
i
Rating by Caroline Palomeque at Noble Financial
3/12/2018Cantor FitzgeraldSet Price TargetBuy$32.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
1/19/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$24.00High
i
12/29/2017Noble FinancialReiterated RatingBuyN/A
i
Rating by Caroline Palomeque at Noble Financial
12/23/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Caroline Palomeque at Noble Financial
12/15/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Caroline Palomeque at Noble Financial
12/14/2017Cantor FitzgeraldSet Price TargetOverweight$24.00 ➝ $28.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
11/8/2017Noble FinancialBoost Price TargetBuy$16.00 ➝ $20.00N/A
i
Rating by Kumaraguru Raja at Noble Financial
9/29/2017Noble FinancialReiterated RatingBuy ➝ Buy$16.00Medium
i
Rating by Kumaraguru Raja at Noble Financial
9/20/2017Cantor FitzgeraldReiterated RatingBuy$24.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
8/9/2017Cantor FitzgeraldSet Price TargetBuy$24.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
8/9/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Mark Jordan at Noble Financial
7/17/2017Cantor FitzgeraldSet Price TargetBuy$24.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
6/16/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Mark Jordan at Noble Financial
6/13/2017Cantor FitzgeraldSet Price TargetBuy$24.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
5/14/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Mark Jordan at Noble Financial
5/9/2017Cantor FitzgeraldSet Price TargetBuy$24.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
5/6/2017Noble FinancialReiterated RatingBuyMedium
i
Rating by Mark Jordan at Noble Financial
4/7/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Mark Jordan at Noble Financial
4/5/2017Cantor FitzgeraldReiterated RatingBuy$24.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
4/3/2017JMP SecuritiesReiterated RatingOutperform$20.00 ➝ $27.00Low
i
3/31/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Mark Jordan at Noble Financial
3/30/2017Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$17.00 ➝ $24.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
3/14/2017Cantor FitzgeraldReiterated RatingBuy$17.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
3/12/2017Noble FinancialReiterated RatingBuyMedium
i
Rating by Mark Jordan at Noble Financial
2/22/2017Cantor FitzgeraldReiterated RatingOverweight$17.00N/A
i
Rating by Elemer Piros at Cantor Fitzgerald
2/16/2017Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Elemer Piros at Cantor Fitzgerald
12/14/2016Cantor FitzgeraldSet Price TargetBuy$17.00N/A
i
11/30/2016AegisReiterated RatingBuy$12.00N/A
i
Rating by robert leboyer at Aegis
11/15/2016Cantor FitzgeraldReiterated RatingBuy$17.00N/A
i
11/15/2016JMP SecuritiesBoost Price TargetOutperform$9.00 ➝ $20.00N/A
i
11/14/2016AegisReiterated RatingBuyN/A
i
Rating by robert leboyer at Aegis
11/11/2016Noble FinancialReiterated RatingBuy$19.00N/A
i
10/26/2016Cantor FitzgeraldReiterated RatingBuy$17.00N/A
i
10/4/2016Cantor FitzgeraldInitiated CoverageBuy$17.00N/A
i
9/19/2016AegisSet Price TargetBuy$12.00N/A
i
Rating by robert leboyer at Aegis
8/21/2016AegisReiterated RatingBuyN/A
i
Rating by R. Leboyer at Aegis
3/31/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Liisa Bayko at JMP Securities
3/7/2016AegisInitiated CoverageBuy$7.00N/A
i
(Data available from 1/20/2016 forward)
Corbus Pharmaceuticals logo
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Read More

Today's Range

Now: $1.74
$1.68
$1.76

50 Day Range

MA: $1.43
$1.25
$1.74

52 Week Range

Now: $1.74
$0.91
$9.78

Volume

5,857,033 shs

Average Volume

7,960,552 shs

Market Capitalization

$146.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Corbus Pharmaceuticals?

The following Wall Street analysts have issued research reports on Corbus Pharmaceuticals in the last twelve months: BTIG Research, HC Wainwright, Jefferies Financial Group Inc., Nomura, Nomura Instinet, Nomura Securities, Oppenheimer Holdings Inc., Roth Capital, Royal Bank of Canada, and Zacks Investment Research.

What is the current price target for Corbus Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Corbus Pharmaceuticals in the last year. Their average twelve-month price target is $26.39, suggesting a possible upside of 1,416.6%. Nomura Securities has the highest price target set, predicting CRBP will reach $112.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $2.50 for Corbus Pharmaceuticals in the next year.

What is the current consensus analyst rating for Corbus Pharmaceuticals?

Corbus Pharmaceuticals currently has 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRBP, but not buy more shares or sell existing shares.

What other companies compete with Corbus Pharmaceuticals?

How do I contact Corbus Pharmaceuticals' investor relations team?

Corbus Pharmaceuticals' physical mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company's listed phone number is 617-963-0100 and its investor relations email address is ir@corbuspharma.com. The official website for Corbus Pharmaceuticals is www.corbuspharma.com.